TNFSF10 and neoplasm: Based on these results, a non-randomized phase I study is currently ongoing in order to evaluate the safety and the anti-tumor effects of adoptively infused ex vivo expanded autologous NK cells against metastatic cancers or hematological malignancies sensitized to NK TRAIL cytotoxicity with bortezomib (134).